Anthera Pharmaceuticals’ CHABLIS-SC1 Phase 3 clinical trial of its investigational therapy blisibimod did not meet its primary endpoint. After 52 weeks of treatment, there was no statistically significant clinical benefit for systemic lupus erythematosus (SLE) patients treated with the drug compared to placebo-treated patients. Blisibimod acts by blocking BAFF, a…
Anthera Pharmaceuticals recently announced that the last patient in the company’s Phase 3 clinical trial, evaluating blisibimod for the treatment of systemic lupus erythematosus, has received the the final dose. The study will be completed and the data analyzed within the next two months, just in time for the upcoming American…
Anthera Pharmaceuticals reported that the company’s Phase 3 clinical trial of blisibimod in patients with severe systemic lupus erythematosus (SLE) began recently with researchers screening the study’s first patient. Called CHABLIS 7.5, the study is the second Phase 3 trial to explore the drug in lupus patients with and without lupus…
Anthera Pharmaceuticals recently announced it has completed the enrolment of patients for its CHABLIS-SC1 Phase 3 study evaluating blisibimod as a lupus treatment. The company expects to have final data from the trial by the end of 2016. “Reaching our enrollment target for CHABLIS-SC1 ahead of schedule is an important accomplishment,” said in…
Anthera Pharmaceuticals, Inc. announced the completion of its Phase 3 trial (CHABLIS-SC1), which evaluated the effect of blisibimod in patients suffering with systemic lupus erythematosus. The CHABLIS-SC1 study was evaluated by an independent statistician to assess the SRI-6 response 24 weeks after the beginning of the…